S
Sarah Sloan
Researcher at Brigham and Women's Hospital
Publications - 20
Citations - 1066
Sarah Sloan is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 12, co-authored 19 publications receiving 958 citations. Previous affiliations of Sarah Sloan include Beth Israel Deaconess Medical Center & New York University.
Papers
More filters
Journal ArticleDOI
What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes? Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial
TL;DR: After acute coronary syndrome, a J- or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130 to 140mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve, which suggests that too low of a pressure may be dangerous.
Journal ArticleDOI
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
Michelle L. O'Donoghue,David A. Morrow,Sotirios Tsimikas,Sarah Sloan,Angela F. Ren,Elaine B. Hoffman,Nihar R. Desai,Scott D. Solomon,Michael J. Domanski,Kiyohito Arai,Stephanie E. Chiuve,Christopher P. Cannon,Frank M. Sacks,Marc S. Sabatine +13 more
TL;DR: Lp(a) is significantly associated with the risk of CV events in patients with established CAD; however, there exists marked heterogeneity across trials, and the prognostic value of Lp( a) in Patients with low cholesterol levels remains unclear.
Journal ArticleDOI
Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease
Marc S. Sabatine,David A. Morrow,James A. de Lemos,Torbjørn Omland,Sarah Sloan,Petr Jarolim,Scott D. Solomon,Marc A. Pfeffer,Eugene Braunwald +8 more
TL;DR: Elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.
Journal ArticleDOI
Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: PCI-PROVE IT: A PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) Substudy
C. Michael Gibson,Yuri B. Pride,Claudia P. Hochberg,Sarah Sloan,Marc S. Sabatine,Christopher P. Cannon +5 more
TL;DR: The reduction in the incidence of TVR was independent of low-density lipoprotein cholesterol and C-reactive protein lowering and may therefore be due, at least in part, to a pleiotropic effect of high-dose statin therapy.
Journal ArticleDOI
Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial
Sean R. Wilson,Marc S. Sabatine,Eugene Braunwald,Sarah Sloan,Sabina A. Murphy,David A. Morrow +5 more
TL;DR: In this article, the authors performed a pilot study to evaluate the clinical sensitivity of a new ultra-sensitive nanoparticle assay for cardiac troponin I (nano-cTnI) and found that myocardial injury was detectable in a substantial proportion of patients presently classified as having unstable angina.